Dr Falk Pharma UK announces the UK launch of Jorveza, the first globally licensed drug approved for the treatment of the immune mediated, chronic and progressive disease of the oesophagus, Eosinophilic Oesophagitis (EoE).

Jorveza is an orodispersable tablet containing the topical corticosteroid budesonide and is specifically designed to deliver directly to the inflammation within the oesophageal mucosa. (NOTES). In a randomised, controlled clinical trial, Jorveza demonstrated high rates of clinical and histological remission and high patient tolerability, with few side effects.1 Its UK launch has been welcomed by clinicians and patient groups as a significant step forward for those living with this debilitating and unpleasant condition.

 

Read the full clinical release here.

More on